Takeda Pharmaceutical Co Ltd ADR
$ 18.28
0.99%
11 Feb - close price
- Market Cap 57,181,393,000 USD
- Current Price $ 18.28
- High / Low $ 18.30 / 18.12
- Stock P/E 78.70
- Book Value 30.99
- EPS 0.23
- Next Earning Report 2026-05-13
- Dividend Per Share $198.00
- Dividend Yield 3.73 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.02 %
- 52 Week High 18.30
- 52 Week Low 12.89
About
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Analyst Target Price
$19.07
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-01-29 | 2025-10-30 | 2025-07-30 | 2025-05-08 | 2025-01-30 | 2024-10-31 | 2024-07-31 | 2024-05-09 | 2024-02-01 | 2023-10-26 | 2023-07-27 | 2023-05-22 |
| Reported EPS | 0.2099 | -0.0253 | 151 | -0.2276 | 0.0478 | 29.07 | 0.1923 | -0.0065 | 33.79 | -15.5 | 28.76 | 0.074 |
| Estimated EPS | None | 0.151 | 0.2006 | -0.166 | 0.63 | 87.45 | 0.1228 | -0.0142 | 0.1085 | 0.1441 | 18.62 | 0.0505 |
| Surprise | 0 | -0.1763 | 150.7994 | -0.0616 | -0.5822 | -58.38 | 0.0695 | 0.0077 | 33.6815 | -15.6441 | 10.14 | 0.0235 |
| Surprise Percentage | None% | -116.755% | 75174.1775% | -37.1084% | -92.4127% | -66.7581% | 56.5961% | 54.2254% | 31042.8571% | -10856.4192% | 54.4576% | 46.5347% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Previous Dividend Records
| Dec 2025 | Jul 2025 | Dec 2024 | Jul 2024 | Dec 2023 | Jul 2023 | Dec 2022 | Jul 2022 | Jul 2021 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2025-12-11 | 2025-07-07 | 2024-12-12 | 2024-07-08 | 2023-12-11 | 2023-07-10 | 2022-12-12 | 2022-07-11 | 2021-07-12 | None |
| Amount | $0.322144 | $0.33901 | $0.326079 | $0.292214 | $0.319068 | $0.30996 | $0.329553 | $0.330062 | $0.406627 | $0.4191 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TAK
2026-02-10 17:29:07
Takeda Pharmaceutical (TSE:4502) has seen a strong rally, with its stock up 41.7% over the last year. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 59.8%, with an intrinsic value of ¥13,839.98 per share compared to its current price of ¥5,565. However, its Price-to-Earnings (P/E) ratio of 77.84x is much higher than the industry average, suggesting it might be overvalued based on earnings.
2026-02-10 11:58:38
The FDA has accepted Takeda's new drug application for oveporexton, a narcolepsy type 1 treatment, granting it Priority Review status. While this marks a significant advancement for the company, Takeda faces financial challenges including a low Altman Z-Score and negative earnings growth, despite being Japan's largest pharmaceutical company with diversified operations. The approval of oveporexton could be a key catalyst for Takeda, which is currently showing signs of potential financial distress and overvaluation in its stock metrics.
2026-02-10 10:58:38
The FDA has granted Priority Review to Takeda's New Drug Application for oveporexton (TAK-861), a potential first-in-class oral orexin receptor 2-selective agonist for narcolepsy type 1. This decision sets a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda's NDA is supported by positive Phase 3 study results and is not expected to significantly impact the company's full-year consolidated forecast for the fiscal year ending March 31, 2026.
2026-02-10 10:58:38
Takeda Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Oveporexton (TAK-861). The FDA also granted Priority Review for Oveporexton, which is being developed as a potential first-in-class therapy for Narcolepsy Type 1. This marks a significant step for Takeda in developing treatments for neurological diseases.
2026-02-10 07:58:38
The U.S. FDA has accepted Takeda's New Drug Application (NDA) for Oveporexton (TAK-861) and granted it priority review. This potential first-in-class therapy is aimed at treating Narcolepsy Type 1. The news was reported by Refinitiv.
2026-02-09 19:29:12
Takeda Pharmaceutical has entered into a multiyear agreement with Iambic Therapeutics, potentially worth up to $1.7 billion in milestone payments, to leverage Iambic's AI-driven drug discovery technologies. This collaboration will provide Takeda access to Iambic’s generative modeling system, NeuralPLexer, to advance small molecule programs in oncology, gastrointestinal, and inflammation. The deal highlights the pharmaceutical industry's growing adoption of AI for drug development, with Iambic's CEO emphasizing its technology's proven validation in patients.
